"Placebo Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
| Descriptor ID |
D015990
|
| MeSH Number(s) |
N05.715.350.350.625 N06.850.490.734.875
|
| Concept/Terms |
Placebo Effect- Placebo Effect
- Effect, Placebo
- Effects, Placebo
- Placebo Effects
|
Below are MeSH descriptors whose meaning is more general than "Placebo Effect".
Below are MeSH descriptors whose meaning is more specific than "Placebo Effect".
This graph shows the total number of publications written about "Placebo Effect" by people in this website by year, and whether "Placebo Effect" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Placebo Effect" by people in Profiles.
-
Protocol for Escitalopram and Language Intervention for Subacute Aphasia (ELISA): A randomized, double blind, placebo-controlled trial. PLoS One. 2021; 16(12):e0261474.
-
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May; 8(5):e334-e343.
-
A virtual experimenter does not increase placebo hypoalgesia when delivering an interactive expectancy manipulation. Sci Rep. 2020 11 23; 10(1):20353.
-
Results of the FUEL Trial. Circulation. 2020 02 25; 141(8):641-651.
-
Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design. Int J Stroke. 2018 08; 13(6):654-661.
-
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13; 134(24):1918-1930.
-
A virtual experimenter to increase standardization for the investigation of placebo effects. BMC Med Res Methodol. 2016 07 18; 16:84.
-
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67.
-
Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep. 2015 May 27; 5:10593.
-
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.